Amgen’s Remicade Biosimilar Gains Approval
FDA has approved an Amgen BLA for Avsola (infliximab-axxq), a biosimilar of Janssen’s Remicade, indicated for treating Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The agency says this is the fourth biosimilar of Remicade (infliximab) to gain approval. To view the approved label for Avsola, click here.